{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:33:04Z","timestamp":1762101184621},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.cct.2011.04.008","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T01:30:55Z","timestamp":1304386255000},"page":"675-684","source":"Crossref","is-referenced-by-count":3,"title":["The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"2007-000278-22","registry":"10.18810\/euctr"},{"clinical-trial-number":"nct01052389","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alberto","family":"Parabiaghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"D'Avanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Tettamanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2011.04.008_bb0005","unstructured":"Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev (2007), p. CD000284"},{"key":"10.1016\/j.cct.2011.04.008_bb0010","unstructured":"Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev (2006), p. CD003082."},{"key":"10.1016\/j.cct.2011.04.008_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.cct.2011.04.008_bb0025","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"issue":"Suppl 18","key":"10.1016\/j.cct.2011.04.008_bb0030","first-page":"S36","article-title":"Abnormalities of glucose metabolism associated with atypical antipsychotic drugs","volume":"65","author":"Newcomer","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0035","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","article-title":"Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials","volume":"56","author":"Tuunainen","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.cct.2011.04.008_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S1121189X00002281","article-title":"Do findings from new trials for schizophrenia fit with existing evidence: not duped\u2026just beguiled?","volume":"16","author":"Adams","year":"2007","journal-title":"Epidemiol Psichiatr Soc"},{"key":"10.1016\/j.cct.2011.04.008_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhealeco.2004.08.001","article-title":"Do new prescription drugs pay for themselves? The case of second-generation antipsychotics","volume":"24","author":"Duggan","year":"2005","journal-title":"J Health Econ"},{"key":"10.1016\/j.cct.2011.04.008_bb0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cct.2004.09.002","article-title":"An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia","volume":"25","author":"Montgomery","year":"2004","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cct.2011.04.008_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2011.04.008_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.cct.2011.04.008_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1192\/bjp.175.3.217","article-title":"Pragmatic randomised controlled trials in psychiatry","volume":"175","author":"Hotopf","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.317.7167.1181","article-title":"Content and quality of 2000 controlled trials in schizophrenia over 50years","volume":"317","author":"Thornley","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2011.04.008_bb0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cct.2011.04.008_bb0090","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0095","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.cct.2011.04.008_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2011.04.008_bb0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0120","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.cct.2011.04.008_bb0125","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4088\/JCP.v62n1201","article-title":"Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action","volume":"62","author":"Stahl","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0130","unstructured":"El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev (2004), p. CD004578."},{"key":"10.1016\/j.cct.2011.04.008_bb0135","unstructured":"Osservatorio nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia-Rapporto nazionale anno 2006. Roma: 2007. http:\/\/www.agenziafarmaco.it\/it\/content\/rapporti-osmed-luso-dei-farmaci-italia; access verified 24\/11\/2010."},{"key":"10.1016\/j.cct.2011.04.008_bb0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain: a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.cct.2011.04.008_bb0145","unstructured":"Irving CB, Adams CE, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev (2006), p. CD003082."},{"key":"10.1016\/j.cct.2011.04.008_bb0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.cct.2011.04.008_bb0155","unstructured":"Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev (2008), p. CD004278."},{"key":"10.1016\/j.cct.2011.04.008_bb0160","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.cct.2011.04.008_bb0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1192\/bjp.177.3.212","article-title":"Causes of the excess mortality of schizophrenia","volume":"177","author":"Brown","year":"2000","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"Joukamaa","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.nmd.0000105996.62105.07","article-title":"Serious cardiovascular events and mortality among patients with schizophrenia","volume":"192","author":"Enger","year":"2004","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.cct.2011.04.008_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"15","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cct.2011.04.008_bb0190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4088\/JCP.v68n0801","article-title":"Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder","volume":"68","author":"Dunayevich","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0195","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0205","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Med"},{"key":"10.1016\/j.cct.2011.04.008_bb0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/01.jcp.0000245563.06660.0f","article-title":"Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 20","key":"10.1016\/j.cct.2011.04.008_bb0220","first-page":"S22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","article-title":"The spurious advance of antipsychotic drug therapy","volume":"373","author":"Tyrer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2011.04.008_bb0230","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1472-8206.2006.00437.x","article-title":"How to deal with multiple endpoints in clinical trials","volume":"20","author":"Neuh\u00e4user","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cct.2011.04.008_bb0235","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0240","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"Br J Psychiatry"},{"issue":"Suppl 18","key":"10.1016\/j.cct.2011.04.008_bb0245","first-page":"S47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0250","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"issue":"Suppl 3","key":"10.1016\/j.cct.2011.04.008_bb0260","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.euroneuro.2006.06.003","article-title":"Differential metabolic effects of antipsychotic treatments","volume":"16","author":"Haupt","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.cct.2011.04.008_bb0265","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2011.04.008_bb0270","first-page":"811","article-title":"Free the data","volume":"341","author":"Steinbrook","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2011.04.008_bb0275","unstructured":"Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HGG, Kissling W, Leucht S. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2009), p. CD006569."},{"key":"10.1016\/j.cct.2011.04.008_bb0280","unstructured":"Bhattacharjee J, El-Sayeh HGG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2008), p. CD006617."},{"key":"10.1016\/j.cct.2011.04.008_bb0285","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2011.04.008_bb0290","first-page":"1905","article-title":"Statistical principles for clinical trials. ICH harmonized tripartite guideline","volume":"18","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.cct.2011.04.008_bb0295","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/appi.ajp.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am J Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171441100098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171441100098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T12:54:22Z","timestamp":1560171262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171441100098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S155171441100098X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2011.04.008","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}